TCGA-UY-A8OB-01A-12R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 69.28383706
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.560
- INTERFERON_ALPHA_RESPONSE+0.560
- G2M_CHECKPOINT+0.510
- DNA_REPAIR+0.440
- INTERFERON_GAMMA_RESPONSE+0.440
- MTORC1_SIGNALING+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.410
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.250
- KRAS_SIGNALING_UP-0.190
- BILE_ACID_METABOLISM-0.150
- UV_RESPONSE_DN-0.140
- SPERMATOGENESIS-0.120
- FATTY_ACID_METABOLISM-0.100
- PEROXISOME-0.020
- MYOGENESIS-0.010
- KRAS_SIGNALING_DN+0.000
- XENOBIOTIC_METABOLISM+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-IQ-A61E-01A-22R-A30B-07 | — | — | 0.888 |
| 2 | MDT-AP-3375 | Med | Medulloblastoma | 0.885 |
| 3 | MDT-AP-0368 | Med | Medulloblastoma | 0.874 |
| 4 | TCGA-ZF-AA4V-01A-11R-A38B-07 | — | — | 0.872 |
| 5 | SRR6013600 | — | cohortA1 | 0.871 |
| 6 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.867 |
| 7 | SRR2932814 | — | — | 0.860 |
| 8 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.859 |
| 9 | TCGA-33-4566-01A-01R-1443-07 | — | cohortA1 | 0.859 |
| 10 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |